Your doctor may recommend Imitrex to treat migraine that occurs with or without an aura. Imitrex injections may also be used to treat cluster headaches. There are some limitations of use for Imitrex.

Imitrex (sumatriptan) is a brand-name drug that’s prescribed for migraine and cluster headaches in adults. As with other drugs, Imitrex can cause side effects, such as dizzy spells. Imitrex is ...

Imitrex (sumatriptan) is a prescription drug that’s used to treat migraine with or without an aura. It’s not known whether Imitrex may be safe to use while pregnant or breastfeeding. If you can become ...

It’s important to note that Imitrex is not approved to help prevent migraine or cluster headaches. The active drug in Imitrex is sumatriptan. And Imitrex is available as the generic drug sumatriptan.

When you get a migraine attack, you want relief right away. For many people, that relief comes from sumatriptan (Imitrex), the original triptan medication. Despite the development of more triptans and ...

Imitrex Nasal Spray and its generic equivalents had a market value of approximately $53.3 million for the 12 months ended December 2020, according to IQVIA. Adult patients with migraines will soon ...

Sumatriptan (as succinate) 4mg/0.5mL, 6mg/0.5mL; for SC inj. Imitrex Injection is supplied as a clear, colorless to pale yellow, sterile, nonpyrogenic solution as either prefilled syringe and/or ...

Sumatriptan (as succinate) 25mg, 50mg, 100mg. 25mg – white, triangular-shaped, film-coated tablets debossed with “I” on one side and “25” on the other in blister packs of 9 tablets. 50mg – white, ...

BRIDGEWATER, N.J. Dr. Reddy’s announced Monday that it has launched an authorized generic version of GlaxoSmithKline’s Imitrex (sumatriptan succinate) tablets in 25mg, 50mg, and 100mg strengths. The ...

RESEARCH TRIANGLE PARK, N.C., Feb. 2 (UPI) -- GlaxoSmithKline said Thursday the Food and Drug Administration approved a new formulation of its migraine treatment Imitrex injection. The approval is for ...

Dr Reddy's Laboratories has posted net income of 1.92 billion rupees, about $39 million, for its fiscal third quarter, up from the like, year-earlier loss of 1.21 billion rupees, boosted by the launch ...